Search Result

Results for "

Sirtuins

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Sirtuin (46) Adiponectin Receptor (1) AMPK (1) Apoptosis (9) Autophagy (2) c-Myc (1) Caspase (1) GABA Receptor (1) HBV (1) Histone Methyltransferase (1) HSP (1) Keap1-Nrf2 (2) Ligands for Target Protein for PROTAC (1) Parasite (4) PGC-1α (1) Phosphatase (3) PPAR (1) Reverse Transcriptase (3) SARS-CoV (4) Topoisomerase (3)
By Research Areas:	Cancer (31) Cardiovascular Disease (11) Infection (7) Inflammation/Immunology (8) Metabolic Disease (11) Neurological Disease (11)
Click Chemistry:	Alkynes (1)

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Peptides

Natural
Products

Click Chemistry

Targets Recommended: Sirtuin

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-156781

Sirtuin-1 inhibitor 1	Sirtuin	Metabolic Disease
Sirtuin-1 inhibitor 1 (Compound 8) is an inhibitor of *Sirtuin*-1 that plays important roles in obesity-induced diabetes and aging-related diseases .

HY-Q49697

Sirtuin modulator 3	Sirtuin	Metabolic Disease Inflammation/Immunology Cancer
Sirtuin modulator 3 (compound 129) is a N-phenyl benzamide derivative, acts as a *sirtuin* modulator .

HY-147234

Sirtuin modulator 2	Sirtuin	Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Sirtuin modulator 2 (Compound 132) is a *sirtuin* modulator with an ED₅₀ equal or less than 50 μM .

HY-124113

4'-Bromo-resveratrol 4′‐BR	Sirtuin Apoptosis	Cancer
4'-Bromo-resveratrol is a potent and dual inhibitor *Sirtuin-1* and *Sirtuin-3*. 4'-Bromo-resveratrol inhibits melanoma cell growth through mitochondrial metabolic reprogramming. 4'-Bromo-resveratrol imparts antiproliferative effects in melanoma cells through a metabolic reprogramming and affecting the cell cycle and apoptosis signaling .

HY-155725

Z26395438	Sirtuin	Others
Z26395438 (compound 1) is a potent Sirtuin-1 inhibitor, with an IC₅₀ value of 1.6 μM .

HY-149524

SIRT5 inhibitor 8	Sirtuin	Cancer
SIRT5 inhibitor 8 (compound 10) is a competitive inhibitor (IC₅₀: 5.38 μM) of sirtuin SIRT5 with anticancer potential .

HY-149525

SIRT5 inhibitor 9	Sirtuin	Cancer
SIRT5 inhibitor 9 (compound 14) is a competitive inhibitor (IC₅₀: 4.07 μM) of sirtuin SIRT5 with anticancer potential .

HY-148322

Sirtuin modulator 5	Sirtuin	Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Sirtuin modulator 5 is a *sirtuin* modulating agent. Sirtuin modulator 5 can activate *SIRT1* with a DC₅₀ value of <50 μM. Sirtuin modulator 5 can be used for increasing the lifespan of a cell and used for the research of variety of diseases including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benfit from increased mitochondrial activity .

HY-119857

AGK7 SIRT2 Inhibitor,Inactive Control	Sirtuin	Neurological Disease
AGK7 is a potent inhibitor of sirtuin 2 (SIRT2). AGK7 rescues alpha-synuclein toxicity and modified inclusion morphology in a cellular model of Parkinson's disease. AGK7 protects against dopaminergic cell death both in vitro and in a Drosophila model of Parkinson's disease .

HY-P3364

Ac-QPKK(Ac)-AMC	Sirtuin	Others
Ac-QPKK(Ac)-AMC is a fluorogenic substrate for sirtuin through sirtuin deacetylation .

HY-168681

Sirtuin-IN-2	Sirtuin
Sirtuin-IN-2 (compound 20) is an inhibitor of *Sirtuin5*, which is a key target for leukemia and breast cancer .

HY-148312

Sirtuin modulator 4	Sirtuin	Cardiovascular Disease Neurological Disease Inflammation/Immunology Cancer
Sirtuin modulator 4 (compound 12) is a *sirtuin* modulator. Sirtuin modulator 4 shows inhibitory effect to *SIRT1* with an EC₅₀ value of 51-100 μM. Sirtuin modulator 4 may be used for the research of increasing the lifespan of a cell, and preventing a wide variety of diseases and disorders including, for example, diabetes, obesity, neurodegenerative diseases, cardiovascular diseases, inflammation and cancer .

HY-124037

SRT 1460 4 Publications Verification	Sirtuin	Cancer
SRT 1460, a potent **Sirtuin-1 (SIRT1) activator with an EC_1.5** value of 2.9 μM, shows good selectivity for activation of SIRT1 versus SIRT2 and SIRT3 (EC1.5>300 μM), and is more potent than Resveratrol and the closest sirtuin homologues .

HY-155988

Sirtuin modulator 6	Sirtuin	Cardiovascular Disease Neurological Disease Metabolic Disease Cancer
Sirtuin modulator 6 (compound 262) increases the lifespan of a cell. Sirtuin modulator 6 can be used for study of diabetes, obesity, neurodegenerative diseases, cardiovascular disease, and so an extracted from patent WO2009064913A1 .

HY-163316

SIRT4-IN-1	Sirtuin	Metabolic Disease Cancer
SIRT4-IN-1 (compound 69) is selective sirtuin 4 (Sirt4) inhibitor with an IC₅₀ of 16 μM.SIRT4-IN-1 shows no relevant effects on other sirtuin isoforms .

HY-112587

MC3482 5 Publications Verification	Sirtuin	Cancer
MC3482 is a specific sirtuin5 (SIRT5) inhibitor.

HY-19759

SRT 2183 2 Publications Verification	Sirtuin Apoptosis	Cancer
SRT 2183 is a selective **Sirtuin-1 (SIRT1) activator with an EC_1.5** value of 0.36 μM . SRT 2183 induces growth arrest and apoptosis, concomitant with deacetylation of STAT3 and NF-κB, and reduction of c-Myc protein levels .

HY-N2673

5-Heptadecylresorcinol 5-n-Heptadecylresorcinol; AR-C17	Sirtuin	Cardiovascular Disease Metabolic Disease
5-Heptadecylresorcinol (AR-C17), a phenolic lipid component, is also an orally active mitochondrial protector. 5-Heptadecylresorcinol improves mitochondrial function via *sirtuin3* signaling pathway, thus alleviates endothelial cell damage and apoptosis. 5-Heptadecylresorcinol induces sirtuin3-mediated autophagy. 5-Heptadecylresorcinol reduces the atherosclerotic plaques in the aortic root region of mice heart. 5-Heptadecylresorcinol can be used for research of atherosclerosis prevention and obesity .

HY-156023

Sirtuin modulator 7	Sirtuin	Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Sirtuin modulator 7 is a sirtuin-modulating compound which may increase the lifespan of a cell, and may be used for research of diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and flushing which would benefit from increased mitochondrial activity .

HY-47822

WAY-354574	Sirtuin	Neurological Disease
WAY-354574 is an active molecule targeting deacetylase (Sirtuin) for the study of Huntington's disease (HD) .

HY-112634

SIRT5 inhibitor 1 5 Publications Verification	Sirtuin	Others
SIRT5 inhibitor 1 is a potent Human Sirtuin 5 deacylase inhibitor, with an IC₅₀ of 0.11 μM.

HY-112427

Sirt2-IN-1	Sirtuin	Inflammation/Immunology Cancer
Sirt2-IN-1 (Compound 9) is a sirtuin 2 (Sirt2) inhibitor with an IC₅₀ of 163 nM .

HY-115453

UBCS039 5+ Cited Publications	Sirtuin Autophagy	Cancer
UBCS039 is the first synthetic, specific **Sirtuin 6 (SIRT6) activator, inducing autophagy in human tumor cells, with an EC₅₀** of 38 μM .

HY-123994

Tenovin-D3 hydrochloride	Sirtuin	Cancer
Tenovin-D3 hydrochloride is a **sirtuin SirT2** inhibitor that increases p21 (CDKN1A) expression in a p53 independent manner .

HY-108986

JFD00244	Sirtuin SARS-CoV	Cancer
JFD00244 is a sirtuin 2 (SIRT2) inhibitor, with anti-tumor effect. JFD00244 is also a Nsp-16 inhibitor against SARS-CoV-2 .

HY-13515

Sirtinol 10+ Cited Publications	Sirtuin Autophagy Apoptosis	Cancer
Sirtinol is a **sirtuin (SIRT) inhibitor, with IC₅₀**s of 48 μM, 57.7 μM and 131 μM for ySir2, hSIRT2 and hSIRT2, respectively .

HY-19758A

Sirtuin modulator 1	Sirtuin	Cancer
Sirtuin modulator 1 is a modulator of SIRTl, a homolog of *SIRT3*, with EC_1.5 of < 1 μM, extracted from patent WO 2010071853 A1, Compound No.4.

HY-NP019

Agkistrodon halys batroxobin	Sirtuin Caspase Apoptosis	Neurological Disease
Agkistrodon halys batroxobin is a thrombin-like serine protease. Agkistrodon halys batroxobin reduces the expression of *Sirt1* and extracellular signal-regulated kinase activation in brain tissue. Agkistrodon halys batroxobin reduces cleaved caspase-3 expression and inhibits neuronal apoptosis in rat .

HY-118343

AC-93253	Sirtuin	Cancer
AC-93253 is a selective, potent *SIRT2* inhibitor. AC93253 can inhibit SIRT2 with an IC₅₀ value of 6 μM. AC93253 can be used for the research of tumors .

HY-162252

SIRT2-IN-12	Sirtuin	Others
SIRT2-IN-12 (Compound 3) is a *SIRT2* inhibitor with a IC₅₀ value of 50 μM .

HY-160617

SIRT2-IN-14	Sirtuin	Neurological Disease
SIRT2-IN-14 (Compound 78) is a selectve inhibitor for *SIRT2* with an IC₅₀ of 0.196 μM .

HY-163676

MI-217	Sirtuin Apoptosis	Cancer
MI-217 is a potent *SIRT3* inhibitor. MI-217 induces MDA-MB-231 apoptosis. MI-217 can be used in the study of breast cancer .

HY-163532

FLS-359	Sirtuin	Infection
FLS-359 is a selective, orally active allosteric modulator for sirtuin 2, with the IC₅₀ of 3 μM. FLS-359 exhibits antiviral activity against RNA and DNA virus, through inhibition of DNA/RNA replication .

HY-169159

SIRT6 activator 2	Sirtuin	Metabolic Disease
SIRT6 activator 2 (compound 31) is a sirtuin 6 activator with anti-lipid accumulation properties. SIRT6 activator 2 significantly downregulates LXR, SREBP-1c, and their target genes associated with lipogenesis, and can be used for research related to lipid metabolism-related diseases .

HY-122936

Tanshindiol C	Histone Methyltransferase Keap1-Nrf2 Sirtuin	Cardiovascular Disease Cancer
Tanshindiol C is a S-adenosylmethionine-competitive EZH2 (Histone Methyltransferase) inhibitor with an IC₅₀ of 0.55 μM for inhibiting the methyltransferase activity. Tanshindiol C is also an activator of both Nrf2 and **Sirtuin 1 (Sirt1)** in macrophages. Tanshindiol C possesses anti-cancer activity, and can be used for atherosclerosis research .

HY-130479

AdipoR agonist 1	Adiponectin Receptor PPAR PGC-1α Sirtuin AMPK	Metabolic Disease
AdipoR agonist 1 (Compound 112254) is an agonist for adiponectin receptor (AdipoR), which activates the transcriptional regulators like peroxisome proliferator-activated receptors (PPARs), peroxisome proliferator-activated receptor gamma coactivator 1α (PGC-1α), sirtuin 1 (SIRT1), and adenylate-activated protein kinase (AMPK). AdipoR agonist 1 is utilized in preventive doping research .

HY-107454

OSS_128167 Maximum Cited Publications 19 Publications Verification	Sirtuin HBV	Infection Metabolic Disease Inflammation/Immunology Cancer
OSS_128167 is a potent selective **sirtuin 6 (SIRT6) inhibitor with IC₅₀s of 89 μM, 1578 μM and 751 μM for SIRT6*, SIRT1 and SIRT2, respectively. OSS_128167 has anti-HBV* activity that inhibits HBV transcription and replication. OSS_128167 has anti-cancer, anti-inflammation and anti-viral effects .

HY-163698

SIRT-IN-4	Sirtuin	Cancer
SIRT-IN-4 is an inhibitor of the NAD+-dependent lysine deacetylase Sirtuin2 (Sirt2) (IC₅₀=0.35 μM). SIRT-IN-4 is a potent *Sirt2* deacetylase inhibitor that reduces cell survival and inhibits the migration of prostate cancer cells. SIRT-IN-4 can be used to study *Sirt2* in cell cycle regulation, gene expression regulation, etc .

HY-139144

YM-08	Sirtuin HSP	Neurological Disease Cancer
YM-08 (Compounds 7a) is a brain-penetrant inhibitors of *SIRT2*,with the IC₅₀ of 19.9 μM. YM-08 also is inhibitor of Hsp70 .

HY-107453

SirReal1-O-propargyl PROTAC Sirt2-binding moiety 1	Ligands for Target Protein for PROTAC	Cancer
SirReal1-O-propargyl is a selective and highly potent **Sirtuin 2 (Sirt2) inhibitor, with an IC₅₀** of 2.4 μM. SirReal1-O-propargyl, the SirReal1-based moiety, binds to the cereblon ligand via a linker to form PROTAC to degrade Sirt2 . SirReal1-O-propargyl is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-117006

E1231 1 Publications Verification 1-{4-[2-(5-Methylfuran-2-yl)quinoline-4-carbonyl]piperazin-1-yl}ethan-1-one	Sirtuin	Cardiovascular Disease
E1231 is an orally active activator of Sirtuin 1 (SIRT1) (EC₅₀=0.83 μM), to modulate cholesterol and lipid metabolism. E1231 interactes with *SIRT1* (K_D=9.61 μM) and deacetylated liver X receptor-alpha (LXRα), and increases ATP-binding cassette transporter A1 (ABCA1) expression. E1231 also reduces atherosclerotic plaque development in ApoE ^-/- mice model. E1231 can be used for research in cholesterol and lipid disorder-related diseases .

HY-111522

RK-9123016	Sirtuin c-Myc	Cancer
RK-9123016 is a potent inhibitor of SIRT2. RK-9123016 inhibits the enzymatic activity of SIRT2 with an IC₅₀ value of 0.18 µM but not other human sirtuin members including SIRT1 and SIRT3 at 100 µM. RK-9123016 increases the acetylation level of eukaryotic translation initiation factor 5A (eIF5A), a physiological substrate of SIRT2, and reduces cell viability of human breast cancer cells accompanied with a decrease in c-Myc expression .

HY-W020111

7-Chloro-4-(piperazin-1-yl)quinoline	Sirtuin Parasite	Infection
7-Chloro-4-(piperazin-1-yl)quinolone is an important scaffold in medicinal chemistry. 7-Chloro-4-(piperazin-1-yl)quinolone is a potent *sirtuin* inhibitor and also inhibits the serotonin uptake (IC₅₀ of 50 μM). 7-Chloro-4-(piperazin-1-yl)quinolone exhibits antimalarial activity on D10 and K1 strains of *P. falciparum* with IC₅₀s of 1.18 μM and 0.97 μM, respectively .

HY-116152

Cipepofol Ciprofol; HSK3486	GABA Receptor Sirtuin Keap1-Nrf2 Apoptosis	Cardiovascular Disease Neurological Disease Inflammation/Immunology Cancer
Cipepofol (Ciprofol), a novel 2,6-disubstituted phenol derivative, is a positive allosteric modulator and direct agonist of the GABA_A receptor. Cipepofol can cause the central nerve inhibition and promote sleep based on the structural modification of Propofol (HY-B0649). Cipepofol can activate the **sirtuin1 (Sirt1)/Nrf2 pathway. Cipepofol protects the heart against Isoproterenol (ISO; HY-B0468)-induced myocardial infarction by reducing cardiac oxidative stress, inflammatory response and cardiomyocyte apoptosis** .

HY-B0879

Suramin	Phosphatase Sirtuin Reverse Transcriptase Topoisomerase SARS-CoV Parasite Apoptosis	Infection Cardiovascular Disease Cancer
Suramin is a reversible and competitive protein-tyrosine phosphatases (PTPases) inhibitor . Suramin is a potent inhibitor of *sirtuins: SirT1 (IC₅₀=297 nM), SirT2 (IC₅₀=1.15 μM), and SirT5 (IC₅₀=22 μM) . Suramin is a competitive inhibitor of reverse transcriptase (DNA topoisomerase II: IC₅₀=5 μM) . Suramin is a potent SARS-CoV-2 RNA-dependent RNA polymerase (RdRp)* inhibitor .Suramin efficiently inhibits IP5K and is an antiparasitic, anti-neoplastic and anti-angiogenic agent .

HY-B0879A

Suramin sodium salt 10+ Cited Publications Suramin hexasodium salt	Phosphatase Sirtuin Reverse Transcriptase Topoisomerase SARS-CoV Parasite Apoptosis	Infection Cardiovascular Disease Cancer
Suramin sodium salt (Suramin hexasodium salt) is a reversible and competitive protein-tyrosine phosphatases (PTPases) inhibitor . Suramin sodium salt is a potent inhibitor of *sirtuins: SirT1 (IC₅₀=297 nM), SirT2 (IC₅₀=1.15 μM), and SirT5 (IC₅₀=22 μM) . Suramin sodium salt is a competitive inhibitor of reverse transcriptase (DNA topoisomerase II: IC₅₀=5 μM) . Suramin sodium salt is a potent SARS-CoV-2 RNA-dependent RNA polymerase (RdRp)* inhibitor . Suramin sodium salt efficiently inhibits IP5K and is an antiparasitic, anti-neoplastic and anti-angiogenic agent .

HY-B0879AR

Suramin sodium salt (Standard)	Phosphatase Sirtuin Reverse Transcriptase Topoisomerase SARS-CoV Parasite Apoptosis	Infection Cardiovascular Disease Cancer
Suramin (sodium salt) (Standard) is the analytical standard of Suramin (sodium salt). This product is intended for research and analytical applications. Suramin sodium salt (Suramin hexasodium salt) is a reversible and competitive protein-tyrosine phosphatases (PTPases) inhibitor . Suramin sodium salt is a potent inhibitor of *sirtuins: SirT1 (IC₅₀=297 nM), SirT2 (IC₅₀=1.15 μM), and SirT5 (IC₅₀=22 μM) . Suramin sodium salt is a competitive inhibitor of reverse transcriptase (DNA topoisomerase II: IC₅₀=5 μM) . Suramin sodium salt is a potent SARS-CoV-2 RNA-dependent RNA polymerase (RdRp)* inhibitor . Suramin sodium salt efficiently inhibits IP5K and is an antiparasitic, anti-neoplastic and anti-angiogenic agent .

Cat. No.	Product Name

HY-L024

Histone Modification Research Compound Library

621 compounds

A histone modification, a covalent post-translational modification (PTM) to histone proteins, includes methylation, phosphorylation, acetylation, ubiquitylation, and sumoylation, etc. In general, histone modifications are catalyzed by specific enzymes that act predominantly at the histone N-terminal tails involving amino acids such as lysine or arginine, as well as serine, threonine, tyrosine, etc. The PTMs made to histones can impact gene expression by altering chromatin structure or recruiting histone modifiers. Histone modifications act in diverse biological processes such as transcriptional activation/inactivation, chromosome packaging, and DNA damage/repair. Deregulation of histone modification contributes to many diseases, including cancer and autoimmune diseases.

MCE owns a unique collection of 621 bioactive compounds targeting Epigenetic Reader Domain, HDAC, Histone Acetyltransferase, Histone Demethylase, Histone Methyltransferase, Sirtuin, etc. Histone Modification Research Compound Library is a useful tool for histone modification research and drug screening.

HY-L034

Anti-Aging Compound Library

4,646 compounds

Aging is a complex biological process characterized by functional decline of tissues and organs, structural degeneration, and reduced adaptability and resistance, all of which contribute to an increase in morbidity and mortality caused by multiple chronic diseases, such as Alzheimer's disease, cancer, and diabetes. Many theories, which fall into two main categories: programmed and error theories, have been proposed to explain the process of aging, but neither of them appears to be fully satisfactory. The programmed theories imply that aging relies on specific gene regulation, and the error theories emphasize the internal and environmental damages accumulated to living organisms. The damage theories proposed the nine hallmarks that were generally considered to contribute to the aging process: genomic instability, telomere attrition, epigenetic alterations, loss of proteostasis, deregulated nutrient-sensing, mitochondrial dysfunction, cellular senescence, stem cell exhaustion, and altered intercellular communication.

MCE Anti-Aging Compound Library contains 4,646 compounds, mainly targeting Sirtuin, mTOR, IGF-1R, AMPK, p53, Telomerase, Mitophagy, Mitochondrial Metabolism, COX, Cytochrome P450, Oxidase, etc. This library is a useful tool for anti-aging research.

HY-L037

Antioxidant Compound Library

1,622 compounds

Oxidative stress is an imbalance of free radicals and antioxidants in the body, which can lead to cell and tissue damage. Oxidative stress can be responsible for the induction of several diseases, both chronic and degenerative, as well as speeding up body aging process and cause acute pathologies. Antioxidants are a class of compounds able to counteract oxidative stress and mitigate its effects on individuals’ health, gained enormous attention from the biomedical research community. Antioxidants have long been substantial and amenable therapeutic arsenals for multifarious diseases such as AD and cancer.

MCE Antioxidant Compound Library contains 1,622 compounds that act as antioxidants for high throughput screening (HTS) and high content screening (HCS). This library is a useful tool for discovery new antioxidants and oxidative stress research.

HY-L199

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

3,150 compounds

Non-alcoholic fatty liver disease (NAFLD) is one of the most common liver diseases worldwide and is the primary liver manifestation of metabolic syndrome. The growth of NAFLD has coincided with the obesity epidemic. NAFLD is composed of excess lipid accumulation in the liver, causing steatotoxicity, and shows a wide range of histopathological abnormalities. NAFLD may progress from simple steatosis to Non-alcoholic steatohepatitis (NASH) with or without fibrosis (NASH), and eventually to cirrhosis and hepatocellular carcinoma. To date, very few drugs have been approved for marketing specifically for the treatment of NAFLD, so increased efforts to develop NAFLD drugs are necessary.

MCE designs a unique collection of 3,150 small molecules with definite or potential anti-NAFLD activity, which is an important tool for studying the pathological mechanism of NAFLD and developing drugs for NAFLD.

Cat. No.	Product Name	Type